Uroplasty's Urgent(R) PC System to be Featured on National Television Program 'The Doctors'

MINNEAPOLIS, April 8 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (NYSE Amex: UPI), a medical device company developing, manufacturing and marketing innovative proprietary products to treat voiding dysfunctions, today announced that Monday, April 12, the company's Urgent® PC Neuromodulation System is expected to be featured in a segment of the popular television program "The Doctors."

The Urgent PC System is a proprietary, minimally invasive, percutaneous tibial nerve stimulation (PTNS) device designed for office-based treatment of urinary urgency, frequency and urge incontinence, symptoms often associated with overactive bladder (OAB).  Local listings and times, which vary, are available through the following link: http://bit.ly/UrgentPConTV.

"Overactive bladder is an important health issue for women and it will be valuable for viewers to learn from 'The Doctors' – a prominent, nationally-syndicated TV program on health issues – about treatment options such as our Urgent PC System," said David Kaysen, President and CEO of Uroplasty. "OAB is a chronic condition affecting approximately 33 million adults in the United States and more attention needs to be paid to it and the spectrum of treatment options that can help patients."

"'The Doctors' program is expected to feature Dr. Kiarash Michel of Comprehensive Urology Medical Group in Los Angeles, a physician currently using Urgent PC," said Mr. Kaysen. "Dr. Michel and one of his patients will discuss the problems she faced prior to treatment, the treatment experience with Urgent PC and her improvement afterward. This adds to attention brought to Urgent PC from previous mentions on local news programs. But this is the first appearance on a nationally syndicated program which is aimed directly at the main demographic population of potential patients who could benefit from Urgent PC therapy."

For more information about the Urgent PC Neuromodulation System, please call (866) 277-0466 or visit www.uroplasty.com.

About the Urgent PC Neuromodulation System

The Urgent PC Neuromodulation System is a proprietary, minimally invasive nerve stimulation device designed for office-based treatment of urge incontinence, urinary urgency and urinary frequency, symptoms often associated with overactive bladder. Application of neuromodulation therapy targets specific nerve tissue and disrupts the signals that lead to these symptoms.  Uroplasty sells the Urgent PC system in the United States, Canada, and countries recognizing the CE mark. Outside of the United States, Urgent PC is also indicated for the treatment of fecal incontinence.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions.  Our primary focus is the continued commercialization of our Urgent® PC system, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence - symptoms often associated with overactive bladder.  We also offer Macroplastique®, an injectable bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency.  Please visit Uroplasty, Inc. at http://uroplasty.com.

For complete information regarding Macroplastique indications, contraindications, warnings, precautions, instructions for use, storage, adverse reactions and disclaimer of warranties, please refer to the Instructions for Use brochure available at the Uroplasty website.

Forward-Looking Information

This press release contains forward-looking statements, which reflect our best estimates regarding future events and financial performance.  These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results.  We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC.  In particular, our ability to continue to grow our Urgent PC sales  is subject to a number of risks, including the risk that third-party payers will provide or continue to provide coverage and reimbursement, or reimburse the providers an amount sufficient to cover their costs and expenses for Urgent PC treatments.

SOURCE Uroplasty, Inc.